Search

Search Constraints

You searched for: Author/Creator Cappuzzo, Federico

Search Results

1. A noninterventional, multinational study to assess PD‐L1 expression in cytological and histological lung cancer specimens. Issue 12 (28th July 2020)

2. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Issue 3 (March 2015)

3. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Issue 3 (March 2015)

4. Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) study. Issue 2 (November 2015)

5. Anaplastic lymphoma kinase gene rearrangements in cytological samples of non–small cell lung cancer: Comparison with histological assessment. Issue 6 (19th March 2014)

6. Anaplastic lymphoma kinase gene rearrangements in cytological samples of non–small cell lung cancer: Comparison with histological assessment. Issue 6 (19th March 2014)

7. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Issue 7 (July 2019)

8. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Issue 5 (May 2019)

9. Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer. Issue 1 (21st November 2019)